en · de · es · pt
liraglutide-notes.peptides7250.com › Topic › Background And Receptor Pharmacology — Reference Sheet

Background And Receptor Pharmacology — Reference Sheet

By Editorial Desk · published 2025-09-08 · last reviewed 2025-10-18 · Topic

aggregation raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.

Reviewed 2025-10-18. Anything still debated is marked as such rather than presented as settled.

Background And Receptor Pharmacology

Tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor, making it a dual agonist rather than a selective agent. Engagement of the GLP-1 receptor is linked to glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. The relative contribution of the GIP arm remains an active research question; proposed roles include improved insulin sensitivity and altered adipose tissue handling. Receptor occupancy studies suggest the molecule interacts with both targets at circulating concentrations achieved during therapy.

Development began in the 2010s, when researchers modified a GIP-based scaffold to add GLP-1 activity and then attached the fatty diacid to lengthen its half-life. Clinical evaluation proceeded through large phase 3 programmes in type 2 diabetes and in obesity, and regulators in the United States cleared the compound for type 2 diabetes in 2022 and for chronic weight management in 2023. Several cardiovascular and metabolic outcome studies are still reporting, so the picture of long-term benefit and risk is incomplete. Approvals in other regions followed on different timelines.

Storage Stability and Analytical Methods

Identity and purity are assessed by reversed-phase high-performance liquid chromatography, with mass confirmation by electrospray ionisation mass spectrometry. Peptide mapping after enzymatic digestion verifies the primary sequence. Size-exclusion chromatography quantifies aggregates, while circular dichroism provides a secondary-structure fingerprint. Bioanalytical quantification in plasma uses immunoassay or LC-MS/MS. Reported purity for research-grade lots is commonly 95 percent or higher, and residual water content is checked by Karl Fischer titration.

As a peptide, tirzepatide is handled as a lyophilised solid in research settings and as a preserved solution in finished products. Aqueous solubility is pH dependent and reaches a minimum near the isoelectric point, which lies close to pH 5.4. Stock solutions are typically prepared in neutral or slightly basic buffer to limit precipitation. The solid is hygroscopic and should be equilibrated to room temperature before opening so that condensation does not form on the powder surface.

Recommended storage for reference material is a freezer at approximately -20 degrees Celsius, protected from light and moisture. Commercial injectable presentations are stored refrigerated between 2 and 8 degrees Celsius and must not be frozen. Product labelling generally permits a limited period at controlled room temperature once dispensed, with the exact window depending on the presentation. Repeated temperature cycling is avoided because it can promote aggregation or deamidation of the peptide chain.

Tirzepatide at a glance

PropertyValueNotes
Molecular formulaC225H348N48O68Peptide backbone with a fatty diacid chain
Molecular weightAbout 4813 DaCalculated from the formula
Receptor targetsGIP and GLP-1 receptorsDual agonist activity at both sites
Route of administrationSubcutaneous injectionNo approved oral form at present
Elimination half-lifeAbout 5 daysSupports extended intervals between administrations

Tirzepatide 分子背景与靶点

当前公开资料把 tirzepatide 归为肠促胰素类受体双重激动剂。它并非激素天然变体,而是经过序列改造的工程化肽。其分子量、等电点与疏水性等基础参数已在药典和化学数据库中收录,可作为分析检测和质量研究的参照。

Tirzepatide 是一种由 39 个氨基酸组成的合成肽,分子结构上以 GIP 序列为骨架并引入脂肪酸侧链修饰,使其能够同时与葡萄糖依赖性促胰岛素多肽(GIP)受体和胰高血糖素样肽-1(GLP-1)受体结合。这种双重激动特性使它在同类肽类药物中区别于选择性 GLP-1 受体激动剂。该分子最早由一家制药公司在 2010 年代报道,随后进入糖尿病与体重管理领域的临床研究。

Related pages on this site

Handling, Storage, and Analytical Methods

Research and analytical settings increasingly require documentation of peptide origin and chain of custody. Certificate of analysis documents typically report purity by chromatographic area, mass confirmation, appearance, and residual solvent or counterion content. Independent verification by an accredited laboratory is common when a material will be used in a regulated study. Open questions remain about how well compendial methods transfer between laboratories, and about which impurity thresholds are meaningful for materials not intended for clinical use.

Peptide-based pharmaceutical products such as tirzepatide require controlled temperature management to preserve structural integrity. Manufacturer labeling generally specifies refrigeration at 2 to 8 degrees Celsius before first use, with protection from light and freezing. Exposure to repeated temperature cycling can promote aggregation or deamidation, which alters the analytical profile even when the visible solution appears unchanged. Once a product is in use, the permitted storage window and temperature range are defined by the specific labeled presentation rather than by general peptide rules.

Notes from published material

In the United States, caregivers for patients with Type 1 diabetes are instructed to have an unexpired glucagon emergency kit on hand at all times. A number of companies are developing glucagon injection devices with the goal of simplifying administration for caregivers and patients during severe hypoglycemic events. For many, the current standard of care (the glucagon emergency kit) is burdensome and not caregiver or patient-friendly due to the multiple steps required to administer the drug, especially during an emergency situation. To improve hypoglycemia treatment, many companies are developing more efficient glucagon delivery solutions. Xeris Pharmaceuticals, Inc. is developing the Glucagon Rescue Pen or G-Pen using a patented non-aqueous formulation of glucagon that is room-temperature stable, low-volume, and pre-mixed in an auto-injectable device (similar to an EpiPen) that takes the injection process down to two steps (as opposed to nine steps with glucagon emergency kits currently on the market). Similarly, GlucaPen, an autoinjector in development by Enject, Inc. promises to simplify the delivery of glucagon.

=== EC 1.7.1 With NAD+ or NADP+ as acceptor === EC 1.7.1.1: nitrate reductase (NADH) EC 1.7.1.2: nitrate reductase (NAD(P)H) EC 1.7.1.3: nitrate reductase (NADPH) EC 1.7.1.4: nitrite reductase (NAD(P)H) EC 1.7.1.5: hyponitrite reductase EC 1.7.1.6: azobenzene reductase EC 1.7.1.7: GMP reductase EC 1.7.1.8: deleted EC 1.7.1.9: nitroquinoline-N-oxide reductase EC 1.7.1.10: hydroxylamine reductase (NADH) EC 1.7.1.11: 4-(dimethylamino)phenylazoxybenzene reductase EC 1.7.1.12: N-hydroxy-2-acetamidofluorene reductase EC 1.7.1.13: preQ1 synthase EC 1.7.1.14: nitric oxide reductase (NAD(P), nitrous oxide-forming) EC 1.7.1.15: nitrite reductase (NADH) EC 1.7.1.16: nitrobenzene nitroreductase EC 1.7.1.17: FMN-dependent NADH-azoreductase

In 1984, Applied Biosystems sales revenue tripled to over US$18 million, with a second yearly profit, and with over 200 employees. Services included synthesizing custom DNA and protein fragments, and the sequencing of protein samples submitted from customers. The third major instrument made by Applied, the Model 430A Peptide Synthesizer, was introduced. In 1985, Applied Biosystems sales revenue grew nearly 70% to over US$35 million, with a third yearly profit. Two new products included the Model 380B DNA Synthesizer and the 381A DNA Synthesizer. That year the company went international for the first time, when it established a wholly owned subsidiary in Great Britain to save shipping costs on chemical sales, which overall by then accounted for 17% of sales. Also in 1985, Applied Biosystems acquired Brownlee Labs, a manufacturer of columns and pumps for high-performance liquid chromatography (HPLC) systems, after its founder, Robert Brownlee was diagnosed with AIDS-related complex in 1984. Brownlee's technology brought the new on-line 120A PTH Amino Acid Analyzer. However, Brownlee then began a new company, which was viewed by Applied as a competitor. In 1989 Applied and Brownlee settled in a lawsuit over the conflict. As late as 1990, Brownlee publicly discussed what had been his contributions in the rocky relationship with Applied, before he died early the next year. In 1986, Andre Marion became president and chief executive officer. Sales revenue increased by 45% to nearly US$52 million. The company introduced six new products, totalling eleven automated instruments.

Nearly 40,000 workers and harvesters in the provinces of Newfoundland and Labrador applied for the federal relief program TAGS (the Atlantic Groundfish Strategy). Abandoned and rusting fishing boats still litter the coasts of Newfoundland and the Canadian northwest to this day. The fishery minister, John Crosbie, after delivering a speech on the day before the declaration of the moratorium, or July 1, 1992, was publicly heckled and verbally harassed by disgruntled locals at a fishing village. The moratorium, initially lasting for only two years, was indefinitely extended after it became evident that cod populations had not recovered at all but, instead, had continued to spiral downward in both size and numbers, due to the damage caused by decades of destructive fishing practices, and the fact that the moratorium had permitted exceptions for food fisheries for "personal consumption" purposes to this very day. Some 12,000 tons of Northwest cod are still being caught every year along the Newfoundland coast by local fishermen. The collapse of the four-million ton biomass, which had persevered through several previous marine extinctions over tens of millions of years, in a timespan of no more than 20 years, is oft-cited by researchers as one of the most visible examples of the phenomenon of the "Tragedy of the Commons." Factors which had been implicated as contributing to the collapse include: overfishing; government mismanagement; the disregard of scientific uncertainty; warming habitat waters; declining reproduction; and plain human ignorance.

== Further reading == Perkins, D. H. (1984-12-01). "Proton Decay Experiments". Annual Review of Nuclear and Particle Science. 34 (1): 1–50. Bibcode:1984ARNPS..34....1P. doi:10.1146/annurev.ns.34.120184.000245. ISSN 0163-8998. Luciano Maiani (8 February 2006). The problem of proton decay (PDF). Third NO-VE International Workshop on Neutrino Oscillations in Venice. Venice. Nath, Pran; Fileviez Pérez, Pavel (April 2007). "Proton stability in grand unified theories, in strings and in branes". Physics Reports. 441 (5–6): 191–317. arXiv:hep-ph/0601023. Bibcode:2007PhR...441..191N. doi:10.1016/j.physrep.2007.02.010. S2CID 119542637. Dev, P. S. B.; et al. (2022-09-26), "Searches for Baryon Number Violation in Neutrino Experiments: A White Paper", Journal of Physics G: Nuclear Physics, 51 (3): 033001, arXiv:2203.08771, Bibcode:2024JPhG...51c3001D, doi:10.1088/1361-6471/ad1658

Sources: en.wikipedia.org

Background from the literature

Estradiol has been studied and used by intranasal administration. It was available as a cyclodextrin-containing nasal spray under the brand name Aerodiol in some countries, although this specific product was discontinued in 2007. The product was administered once per day as one 150-μg spray in each nostril (300 μg/day total). Intranasal estradiol has pharmacokinetics similar to those of sublingual and intravenous administration of estradiol, including a sharp peak and then rapid decline in estradiol levels. Despite the relatively short duration of intranasal estradiol, it has similar effectiveness to other, longer-lasting routes of administration in terms of relief of menopausal symptoms like hot flashes.

==== Health claims ==== The Japanese Ministry of Health, Labor, and Welfare (MHLW) set up the 'Foods for Specified Health Uses' (特定保健用食品; FOSHU) regulatory system in 1991 to individually approve the statements made on food labels concerning the effects of foods on the human body. The regulatory range of FOSHU was later broadened to allow for the certification of capsules and tablets. In 2001, MHLW enacted a new regulatory system, 'Foods with Health Claims' (保健機能食品; FHC), which consists of the existing FOSHU system and the newly established 'Foods with Nutrient Function Claims' (栄養機能表示食品; FNFC), under which claims were approved for any product containing a specified amount per serving of 12 vitamins, including vitamin B6, and two minerals. To make a health claim based on a food's vitamin B6 content, the amount per serving must be in the range of 0.3–25 mg. The allowed claim is: "Vitamin B6 is a nutrient that helps produce energy from protein and helps maintain healthy skin and mucous membranes." In 2010, the European Food Safety Authority (EFSA) published a review of proposed health claims for vitamin B6, disallowing claims for bone, teeth, hair skin and nails, and allowing claims that the vitamin provided for normal homocysteine metabolism, normal energy-yielding metabolism, normal psychological function, reduced tiredness and fatigue, and provided for normal cysteine synthesis. The US Food and Drug Administration (FDA) has several processes for permitting health claims on food and dietary supplement labels.

The premise of Cry Freedom is based on the true story of Steve Biko, the charismatic South African Black Consciousness Movement leader who attempts to bring awareness to the injustice of apartheid, and Donald Woods, the liberal white editor of the Daily Dispatch newspaper who struggles to do the same after Biko is murdered. In 1972, Biko was one of the founders of the Black People's Convention working on social upliftment projects around Durban. The BPC brought together almost 70 different black consciousness groups and associations, such as the South African Student's Movement (SASM), which played a significant role in the 1976 uprisings, and the Black Workers Project, which supported black workers whose unions were not recognised under the apartheid regime. Biko's political activities eventually drew the attention of the South African Government which often harassed, arrested, and detained him. These situations resulted in his being 'banned' in 1973. The banning restricted Biko from talking to more than one person at a time, in an attempt to suppress the rising anti-apartheid political movement. Following a violation of his banning, Biko was arrested and later killed while in the custody of the South African Police (the SAP). The circumstances leading to Biko's death caused worldwide anger, as he became a martyr and symbol of black resistance. As a result, the South African Government 'banned' a number of individuals (including Donald Woods) and organisations, especially those closely associated with Biko.

Hydrophobins have been found to be structurally and functionally similar to cerato-platanins, another group of small cysteine-rich proteins, which also contain a high percentage of hydrophobic amino acids, and are also associated with hyphal growth. This family of proteins includes the rodlet proteins of Neurospora crassa (gene eas) and Emericella nidulans (gene rodA), these proteins are the main component of the hydrophobic sheath covering the surface of many fungal spores. Genomic sequencing of two fungi from dry or salty environments (Wallemia sebi and W. ichthyophaga) revealed that these species contain predicted hydrophobins with unusually high proportion of acidic amino acids and therefore with potentially novel characteristics. High proportion of acidic amino acids is thought to be an adaptation of proteins to high concentrations of salt.

Sources: en.wikipedia.org

Reference notes

It was tested as much in animals as in humans and, very rarely, did it cause serious side effects including paralysis of the legs and death. It could also cause anaphylaxis, but it was only seen in 1% of the patients who received the medication. The sale and distribution of chymopapain was discontinued in the United States on January 27, 2003, after the company producing it decided to stop selling it worldwide.

=== Corporate self-regulation === AI labs and companies generally abide by safety practices and norms that fall outside of formal legislation. One aim of governance researchers is to shape these norms. Examples of safety recommendations found in the literature include performing third-party auditing, offering bounties for finding failures, sharing AI incidents (an AI incident database was created for this purpose), following guidelines to determine whether to publish research or models, and improving information and cyber security in AI labs. Companies have also made commitments. Cohere, OpenAI, and AI21 proposed and agreed on "best practices for deploying language models", focusing on mitigating misuse. To avoid contributing to racing-dynamics, OpenAI has also stated in their charter that "if a value-aligned, safety-conscious project comes close to building AGI before we do, we commit to stop competing with and start assisting this project" Also, industry leaders such as CEO of DeepMind Demis Hassabis, director of Facebook AI Yann LeCun have signed open letters such as the Asilomar Principles and the Autonomous Weapons Open Letter.

On the first day, they'd have 100 mg in their system; their body would clear 10 mg, leaving 90 mg. On the second day, the patient would have 190 mg in total; their body would clear 19 mg, leaving 171 mg. On the third day, they'd be up to 271 mg total; their body would clear 27 mg, leaving 244 mg. As one can see, it would take many days for the total amount of drug within the body to come close to 1 gram (1000 mg) and achieve its full therapeutic effect. For a drug such as this, a doctor might prescribe a loading dose of one gram to be taken on the first day. That immediately gets the drug's concentration in the body up to the therapeutically-useful level.

Engorgement is the swelling and stretching of the breast tissue due to the accumulation of fluid in the tissue surrounding and supporting the milk-producing cells and ducts. Engorgement most frequently occurs as milk "comes in" and during the weaning process. As milk is coming in, several processes occur. At the end of pregnancy, the blood vessels that supply the breast dilate, allowing for leaking into the tissue or interstitial space. Additionally, the birth of an infant is followed by massive fluid shifts to both offload excess fluid, which had been used to supply oxygen and nutrients to the fetus through the placenta, which is no longer needed, and supply additional fluid to the breasts to start the process of making milk. These fluid shifts often result in some of this excess fluid leaking into the breast tissue. Finally, milk "coming in" can create an uncomfortably full feeling, which, combined with the aforementioned fluid accumulation in the breast tissue, can cause severe pain. If breastfeeding is suddenly stopped, the breasts are likely to become engorged. Pumping small amounts to relieve discomfort helps to train the breasts to produce less milk gradually. There is presently no safe medication to prevent engorgement, but cold compresses and ibuprofen may help to relieve pain and swelling. Pain should go away with emptying of the breasts. If symptoms persist and comfort measures are not helpful, a blocked milk duct or infection may be present, and the affected person should seek medical intervention.

=== Polymers === In polymer chemistry, MALDI can be used to determine the molar mass distribution. Polymers with polydispersity greater than 1.2 are difficult to characterize with MALDI due to the signal intensity discrimination against higher mass oligomers. A good matrix for polymers is dithranol or AgTFA. The sample must first be mixed with dithranol and the AgTFA added afterwards; otherwise the sample will precipitate out of solution.

Sources: en.wikipedia.org

Frequently asked questions

What is tirzepatide?

It is a synthetic 39-amino-acid peptide that acts on two incretin receptors, the GIP receptor and the GLP-1 receptor. It is given by subcutaneous injection and has a circulating half-life of roughly five days. It is not a small molecule and is not absorbed usefully from the gut in conventional oral form.

How does it differ from selective GLP-1 receptor agonists?

Selective agents act on one receptor, while tirzepatide engages both GIP and GLP-1 receptors. The added GIP activity may contribute effects on insulin sensitivity and on fat metabolism. Whether the dual action produces meaningful clinical advantages beyond differences in potency is still being examined.

Which parts of its mechanism remain uncertain?

The downstream consequences of GIP receptor activation are not fully characterised in humans. It is also unclear how much each receptor contributes to appetite reduction and to shifts in body composition. Published work describes associations and proposed pathways rather than settled causal chains.

How should reference material be stored?

Solid material is normally kept frozen at about -20 degrees Celsius, desiccated and protected from light. Solutions are held cold and used within a defined window because degradation products accumulate over time.

Network